# A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers

> **NCT05738993** · PHASE1 · UNKNOWN · sponsor: **Biocad** · enrollment: 100 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** BCD-178
- **DRUG:** Perjeta

## Key facts

- **NCT ID:** NCT05738993
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-08
- **Primary completion:** 2023-04-30
- **Final completion:** 2024-01-31
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05738993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05738993, "A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05738993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*